Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Assets Average (2016 - 2025)

Historic Assets Average for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $354.9 million.

  • Akebia Therapeutics' Assets Average rose 6608.56% to $354.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $354.9 million, marking a year-over-year increase of 6608.56%. This contributed to the annual value of $231.2 million for FY2024, which is 2264.87% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Assets Average is $354.9 million, which was up 6608.56% from $327.9 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Assets Average high stood at $636.4 million for Q1 2021, and its period low was $213.7 million during Q3 2024.
  • Its 5-year average for Assets Average is $383.6 million, with a median of $327.9 million in 2025.
  • Its Assets Average has fluctuated over the past 5 years, first plummeted by 5011.2% in 2023, then surged by 6608.56% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Assets Average (Quarter) stood at $565.8 million in 2021, then decreased by 29.28% to $400.2 million in 2022, then crashed by 40.44% to $238.4 million in 2023, then fell by 10.26% to $213.9 million in 2024, then soared by 65.9% to $354.9 million in 2025.
  • Its last three reported values are $354.9 million in Q3 2025, $327.9 million for Q2 2025, and $265.4 million during Q1 2025.